Scholar Rock Holding (SRRK) Receivables (2019)

Scholar Rock Holding (SRRK) recorded quarterly Receivables of $25.0 million in Q4 2019.

Scholar Rock Holding (SRRK) Receivables (2019) Analysis & Trends

Scholar Rock Holding's Receivables history runs 1 years deep, the most recent figure standing at $25.0 million for Q4 2019.

In Q4 2019, Receivables changed N/A year-over-year to $25.0 million; the TTM figure through Dec 2019 stood at $25.0 million (changed N/A YoY), while the FY2019 annual figure was $25.0 million, changed N/A from the prior year.
Receivables was $25.0 million for Q4 2019 at Scholar Rock Holding.
In the past five years, Receivables ranged from a high of $25.0 million in Q4 2019 to a low of $25.0 million in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Scholar Rock Holding	6.03 Bn	5.55 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2019	25.00 Mn